Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its newer products will offset the loss of revenue from patent expirations and ...
AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
The treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial [HeFH]) or mixed dyslipidemia, as an adjunct to diet: in combination with a statin or statin with ...
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results